论文部分内容阅读
目的探讨慢性乙型肝炎患者拉米夫定耐药后采用拉米夫定联合阿德福韦酯进行后续抗病毒的治疗效果。方法74例拉米夫定耐药患者,分治疗组和对照组。治疗组38例,用拉米夫定联合阿德福韦酯,疗程1年;对照组36例继续应用拉米夫定,疗程1年。定期进行血清肝功能和病毒学指标检测。结果治疗结束时治疗组肝功复常率HBVRNA阴转率和HBeAg/抗HBe转换率均明显高于对照组(P<0.01)。结论慢性乙型肝炎患者拉米夫定耐药后采用拉米夫定联合阿德韦酯进行后续抗病毒治疗是有益的。
Objective To investigate the therapeutic effect of lamivudine combined with adefovir dipivoxil on subsequent antiviral therapy in patients with chronic hepatitis B after lamivudine resistance. Methods 74 cases of lamivudine resistant patients, divided into treatment group and control group. Treatment group 38 cases, with lamivudine combined with adefovir dipivoxil treatment for 1 year; control group, 36 cases continued lamivudine treatment for 1 year. Regular serum liver function and virological detection. Results At the end of treatment, the normal rate of liver function recovery and HBeAg / anti-HBe conversion rate in the treatment group were significantly higher than those in the control group (P <0.01). Conclusion Lamivudine combined with adeviride after lamivudine resistance in patients with chronic hepatitis B is beneficial for follow-up antiviral therapy.